1. Home
  2. AYTU vs DPRO Comparison

AYTU vs DPRO Comparison

Compare AYTU & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • DPRO
  • Stock Information
  • Founded
  • AYTU N/A
  • DPRO 1998
  • Country
  • AYTU United States
  • DPRO Canada
  • Employees
  • AYTU N/A
  • DPRO N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • DPRO Aerospace
  • Sector
  • AYTU Health Care
  • DPRO Industrials
  • Exchange
  • AYTU Nasdaq
  • DPRO Nasdaq
  • Market Cap
  • AYTU 10.5M
  • DPRO 9.3M
  • IPO Year
  • AYTU N/A
  • DPRO N/A
  • Fundamental
  • Price
  • AYTU $1.72
  • DPRO $2.96
  • Analyst Decision
  • AYTU
  • DPRO Strong Buy
  • Analyst Count
  • AYTU 0
  • DPRO 2
  • Target Price
  • AYTU N/A
  • DPRO $7.00
  • AVG Volume (30 Days)
  • AYTU 27.9K
  • DPRO 332.5K
  • Earning Date
  • AYTU 02-12-2025
  • DPRO 11-14-2024
  • Dividend Yield
  • AYTU N/A
  • DPRO N/A
  • EPS Growth
  • AYTU N/A
  • DPRO N/A
  • EPS
  • AYTU N/A
  • DPRO N/A
  • Revenue
  • AYTU $79,759,000.00
  • DPRO $4,340,793.00
  • Revenue This Year
  • AYTU N/A
  • DPRO $14.33
  • Revenue Next Year
  • AYTU N/A
  • DPRO $115.93
  • P/E Ratio
  • AYTU N/A
  • DPRO N/A
  • Revenue Growth
  • AYTU N/A
  • DPRO N/A
  • 52 Week Low
  • AYTU $1.30
  • DPRO $1.55
  • 52 Week High
  • AYTU $3.45
  • DPRO $11.75
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 54.22
  • DPRO 37.68
  • Support Level
  • AYTU $1.68
  • DPRO $3.17
  • Resistance Level
  • AYTU $1.93
  • DPRO $3.92
  • Average True Range (ATR)
  • AYTU 0.12
  • DPRO 0.44
  • MACD
  • AYTU 0.00
  • DPRO -0.16
  • Stochastic Oscillator
  • AYTU 36.36
  • DPRO 13.93

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

Share on Social Networks: